Who Paid My Doc
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Grou
Research payments
$471,546
Through program year 2025, $471,546 in research payments was reported against A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Grou, across 132 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $414,329 | 115 |
| 2024 | Research | $57,217 | 17 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Faye Pais Gainesville, FL Named on 17 payments
- Lake Morrison Durham, NC Named on 16 payments
- Ivan Rosas Houston, TX Named on 14 payments
- Mary Scholand Farmington, UT Named on 13 payments
- Rohit Gupta Oaks, PA Named on 13 payments
- Maria Padilla New York, NY Named on 9 payments
- Toby Maher Los Angeles, CA Named on 7 payments
- Lisette Delgado Sanchez Naples, FL Named on 7 payments
- Munish Sharma Temple, TX Named on 7 payments
- Adam Kilian Saint Louis, MO Named on 5 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.